White Papers
Right Sizing Your Quality Management System
Determining the right size of a Quality Management System (QMS) can make some feel like they are on a roller coaster ride and not know how to navigate the numerous drops and turns. Although developing a QMS is a requirement, it does not need to be overwhelming....
The Future of Clinical Trials: Decentralized Trial Considerations
Decentralized Clinical Trials (DCT) are here to stay! In 2007, the FDA and Duke University partnered to develop and drive the adoption of practices for increased quality and efficiency of clinical trials and formed Clinical Trials Transformation Initiative (CTTI)....
Revolutionizing Healthcare: The Emergence of Al-Powered Medical Devices
The integration of Artificial Intelligence in medical devices is revolutionizing healthcare delivery, with the potential to improve patient outcomes, reduce costs, and increase access to care. From diagnostic systems to imaging devices, AI is being used in various...
White Paper – FDA Guidance Documents for De Novo Classification Requests
The De Novo classification process is a risk-based approach for classifying novel medical devices that had previously been automatically placed in Class III, the highest United States device classification. On October 4, 2021, the US Food and Drug Administration (FDA)...
White Paper – Transition Plan for COVID19 EUAs
White Paper on Transition Plan for Medical Devices that fall within enforcement policies and EUAs issued during the COVID-19 Public Health Emergency. The FDA has provided their thoughts on 180-day transition plans to get back to standard practices (compliance with the...
White Paper – Proposed QMSR Expert Analysis (Part 2)
On Feb. 23, 2022, the U.S. FDA published the Draft Proposed Rulemaking for the new “Quality Management System Regulation.” It’s imperative that the entire industry thoroughly understand the new proposal and any nuances. This White Paper is Part 2 of a series of...